VAS response to treatment
Compared with placebo, patients receiving mepolizumab had significantly increased odds (odds ratio [OR] 2.19–2.68) of achieving a meaningful improvement in individual VAS scores, based on meeting or exceeding the meaningful within-patient change thresholds at Weeks 49–52 (Fig. Probability of meaningful within-patient changeChange from baseline at Weeks 49–52 in individual VAS scores. *Change from baseline in loss of sense of smell VAS score by surgery number. 